Stockscreener 앱 받기
35.01
3.98%
1.34
시간 외 거래:
35.01
전일 마감가:
$33.67
열려 있는:
$33.96
하루 거래량:
1.12M
Relative Volume:
0.98
시가총액:
$2.51B
수익:
-
순이익/손실:
$-368.95M
주가수익비율:
-6.3135
EPS:
-5.5453
순현금흐름:
$-293.81M
1주 성능:
+10.72%
1개월 성능:
-6.19%
6개월 성능:
-27.86%
1년 성능:
+65.53%
1일 변동 폭
$33.69
$35.70
1주일 범위
$31.05
$35.70
52주 변동 폭
$19.07
$56.05
베라 테라 Stock (VERA) Company Profile
명칭
Vera Therapeutics Inc
전화
650-770-0077
주소
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Compare VERA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
35.01 | 2.46B | 0 | -368.95M | -293.81M | -5.5453 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
베라 테라 Stock (VERA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-10-16 | 개시 | BofA Securities | Buy |
| 2025-08-04 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-05 | 재개 | H.C. Wainwright | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2025-01-28 | 개시 | Goldman | Buy |
| 2024-11-21 | 개시 | Wells Fargo | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-25 | 개시 | Oppenheimer | Outperform |
| 2024-01-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-12-18 | 개시 | Raymond James | Outperform |
| 2023-11-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-16 | 개시 | Guggenheim | Buy |
| 2023-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-04 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-12 | 개시 | JP Morgan | Overweight |
| 2022-05-02 | 개시 | H.C. Wainwright | Buy |
| 2022-04-19 | 개시 | Wedbush | Outperform |
모두보기
베라 테라 주식(VERA)의 최신 뉴스
Vera Therapeutics (VERA) Receives a Buy from Wells Fargo - The Globe and Mail
Vera Therapeutics moves closer to full approval for kidney disease drug after FDA alignment - MSN
Will FDA Alignment on Atacicept’s eGFR Plan Reshape Vera Therapeutics’ (VERA) IgA Nephropathy Narrative - Yahoo Finance
CLDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
A Look At Vera Therapeutics (VERA) Valuation After FDA Alignment On Accelerated IgA Nephropathy Trial Analysis - Yahoo Finance
(VERA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Solid Biosciences (SLDB) - The Globe and Mail
Vera Therapeutics grants inducement awards to 10 new employees - scanx.trade
symbol__ Stock Quote Price and Forecast - CNN
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Grants Inducement Stock Awards to New Employees - Quiver Quantitative
Vera Therapeutics gives new hires 28,800 stock option shares - Stock Titan
Cantor Fitzgerald Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Goldman Sachs Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $90 - Moomoo
Jefferies reiterates Vera Therapeutics stock rating on FDA alignment By Investing.com - Investing.com Canada
Vera Therapeutics stock gets Outperform rating from William Blair By Investing.com - Investing.com Canada
Vera Therapeutics advances FDA timeline for atacicept review - Investing.com UK
Why is Vera Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Vera Therapeutics Advances Atacicept for IgA Nephropathy with FDA Agreement - Intellectia AI
Wolfe Research reiterates Vera Therapeutics stock rating on regulatory path - Investing.com
Wolfe Research reiterates Vera Therapeutics stock rating on regulatory path By Investing.com - Investing.com Canada
Vera Therapeutics Gains FDA Alignment For Kidney Disease Drug, But Stock Drops - Stocktwits
Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment - Yahoo Finance
Vera Therapeutics Aligns With FDA on Earlier Atacicept Analysis to Support Potential Full Approval - marketscreener.com
Goldman Sachs reiterates Vera Therapeutics stock rating on FDA timeline By Investing.com - Investing.com Canada
Vera Therapeutics, Inc. Files Form 8-K with SEC Detailing Company Information and Nasdaq Listing - Minichart
Why is Vera Therapeutics stock sliding today? - Investing.com
Raymond James reiterates Strong Buy on Vera Therapeutics stock By Investing.com - Investing.com Canada
Vera Therapeutics advances FDA timeline for atacicept review By Investing.com - Investing.com Australia
Vera Therapeutics stock rating reiterated at Buy by TD Cowen on FDA alignment - Investing.com Canada
Vera Therapeut aligns with FDA on earlier ORIGIN 3 eGFR analysis; eGFR readout in Q3 2026 - TradingView
Atacicept approval path detailed by Vera Therapeutics (NASDAQ: VERA) - Stock Titan
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to ... - Caledonian Record
FDA, Vera move up kidney trial analysis for potential new IgA nephropathy drug - Stock Titan
VERA News | VERA THERAPEUTICS INC (NASDAQ:VERA) - ChartMill
Vera Therapeutics, Inc. Files Form 8-K Detailing Company Information and SEC Compliance (May 21, 2026) - Minichart
Liquidity Mapping Around (VERA) Price Events - Stock Traders Daily
Vera Therapeutics: Strong IgAN Data, But Differentiation Is Still Pending (NASDAQ:VERA) - Seeking Alpha
[8-K] Vera Therapeutics, Inc. Reports Material Event - Stock Titan
Director at Vera Therapeutics (VERA) receives 17,084 stock options with $34.35 strike - Stock Titan
[Form 4] Vera Therapeutics, Inc. Insider Trading Activity - Stock Titan
Vera Therapeutics (VERA) director Beth Seidenberg receives 17,084-share stock option grant - Stock Titan
Director at Vera Therapeutics (VERA) receives grant of 17,084 options - Stock Titan
Vera Therapeutics grants 17,084-share option to director | VERA Insider Trading - Stock Titan
Vera Therapeutics (VERA) director awarded options on 17,084 shares - Stock Titan
Vera Therapeutics (VERA) awards director 17,084 stock options - Stock Titan
Director Patrick Enright awarded 17,084 Vera Therapeutics (VERA) stock options - Stock Titan
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing - The Motley Fool
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $86 - Moomoo
BofA Securities Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $65 - Moomoo
Vera Therapeutics (VERA) Is Down 11.6% After Wider Q1 Loss Highlights Rising Cost Burden - Sahm
베라 테라 (VERA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):